Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12157103 | 1.00 | TRPA1 (0.34) | TRPA1ALDH1A1CYP2C19 | |
| SCHEMBL4546329 | 1.00 | TRPA1 (0.34) | TRPA1ALDH1A1CYP2C19 | |
| SCHEMBL12173967 | 0.90 | — | — | |
| SCHEMBL4611082 | 0.77 | CHRM2 (0.40) | ALDH1A1CYP2C19 | |
| SCHEMBL4544318 | 0.77 | CHRM2 (0.40) | ALDH1A1CYP2C19 | |
| SCHEMBL12157105 | 0.77 | CHRM2 (0.40) | ALDH1A1CYP2C19 | |
| SCHEMBL31564984 | 0.75 | ALDH1A1 (0.33) | TRPA1ALDH1A1 | |
| SCHEMBL10775509 | 0.74 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL7064509 | 0.74 | NPSR1 (0.32) | — | |
| SCHEMBL14944752 | 0.73 | ALDH1A1 (0.39) | TRPA1ALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020041270-A1 | COLLECTIONS OF PEPTIDES, PEPTIDE AGENTS, AND METHODS OF USE THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2020-02-27 | — | — | WO | disclosed |
| US-9115169-B2 | Method of treating tumors | LYTIX BIOPHARMA AS (NO) | 2015-08-25 | — | — | US | disclosed |
| US-9115169-B2 | Method of treating tumors | LYTIX BIOPHARMA AS (NO) | 2015-08-25 | — | — | US | disclosed |
| US-20120108520-A1 | Antimicrobial Compounds and Formulations | LYTIX BIOPHARMA AS (NO) | 2012-05-03 | — | — | US | disclosed |
| US-8048852-B2 | Antimicrobial compounds and formulations | LYTIX BIOPHARMA AS (NO) | 2011-11-01 | — | — | US | disclosed |
| US-20100267621-A1 | Antimicrobial Compounds and Formulations | LYTIX BIOPHARMA AS (NO) | 2010-10-21 | — | — | US | disclosed |
| US-7232803-B2 | Antimicrobial compounds and formulations | LYTIX BIOPHARMA AS (NO) | 2007-06-19 | — | — | US | disclosed |
| US-7232803-B2 | Antimicrobial compounds and formulations | LYTIX BIOPHARMA AS (NO) | 2007-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108520-A1 | Antimicrobial Compounds and Formulations | VIP, NONO, CLPTM1 | TRPA1 1003/4885ALDH1A1 4792/4885CYP2C19 4104/4885 |
| US-20100267621-A1 | Antimicrobial Compounds and Formulations | VIP, NONO, CLPTM1 | TRPA1 1003/4885ALDH1A1 4792/4885CYP2C19 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.